Weekly Research Analysts’ Ratings Updates for Xenon Pharmaceuticals (XENE)

Several brokerages have updated their recommendations and price targets on shares of Xenon Pharmaceuticals (NASDAQ: XENE) in the last few weeks:

• 3/16/2026 – Xenon Pharmaceuticals had its price target lowered by Wedbush from $64.00 to $63.00. They now have an “outperform” rating on the stock.
• 3/10/2026 – Xenon Pharmaceuticals had its price target raised by Wells Fargo & Company from $49.00 to $68.00. They now have an “overweight” rating on the stock.
• 3/10/2026 – Xenon Pharmaceuticals had its price target raised by Wedbush from $47.00 to $64.00. They now have an “outperform” rating on the stock.
• 3/10/2026 – Xenon Pharmaceuticals had its price target raised by HC Wainwright from $53.00 to $74.00. They now have a “buy” rating on the stock.
• 3/10/2026 – Xenon Pharmaceuticals had its price target raised by Deutsche Bank Aktiengesellschaft from $56.00 to $90.00. They now have a “buy” rating on the stock.
• 3/9/2026 – Xenon Pharmaceuticals was given a new $100.00 price target by Jefferies Financial Group Inc..
• 3/9/2026 – Xenon Pharmaceuticals had its “buy” rating reaffirmed by Guggenheim. They now have a $90.00 price target on the stock.
• 3/9/2026 – Xenon Pharmaceuticals was given a new $97.00 price target by Morgan Stanley.
• 3/9/2026 – Xenon Pharmaceuticals had its price target raised by Robert W. Baird from $63.00 to $97.00. They now have an “outperform” rating on the stock.
• 3/9/2026 – Xenon Pharmaceuticals had its “buy” rating reaffirmed by Bank of America Corporation.
• 3/9/2026 – Xenon Pharmaceuticals had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $65.00 price target on the stock.
• 3/9/2026 – Xenon Pharmaceuticals had its price target raised by Needham & Company LLC from $58.00 to $80.00. They now have a “buy” rating on the stock.
• 2/27/2026 – Xenon Pharmaceuticals had its price target raised by Needham & Company LLC from $55.00 to $58.00. They now have a “buy” rating on the stock.
• 2/27/2026 – Xenon Pharmaceuticals had its price target raised by Wells Fargo & Company from $48.00 to $49.00. They now have an “overweight” rating on the stock.
• 2/23/2026 – Xenon Pharmaceuticals is now covered by Wolfe Research. They set an “outperform” rating and a $60.00 price target on the stock.
• 2/23/2026 – Xenon Pharmaceuticals is now covered by Wolfe Research. They set an “outperform” rating and a $60.00 price target on the stock.
• 2/10/2026 – Xenon Pharmaceuticals was given a new $66.00 price target by Stifel Nicolaus.

Insiders Place Their Bets

In other news, insider Christopher John Kenney sold 1,410 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $55.23, for a total transaction of $77,874.30. Following the completion of the sale, the insider owned 7,069 shares of the company’s stock, valued at approximately $390,420.87. This trade represents a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ian Mortimer sold 7,308 shares of Xenon Pharmaceuticals stock in a transaction on Friday, March 13th. The stock was sold at an average price of $55.23, for a total transaction of $403,620.84. Following the completion of the sale, the chief executive officer owned 19,923 shares of the company’s stock, valued at approximately $1,100,347.29. This trade represents a 26.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 336,707 shares of company stock worth $19,622,565 in the last three months. 4.07% of the stock is owned by insiders.

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.